CARG-BC评分:预测早期乳腺癌老年患者化疗严重毒性的风险工具
该研究基于16家机构≥65岁I-III期乳腺癌患者的前瞻性数据,开发并验证了CARG-BC评分,用于预测3-5级化疗毒性。开发队列中低、中、高风险组毒性发生率分别为19%、54%、87%(P<.01),验证队列为27%、45%、76%,AUC分别为0.75和0.69。
要点
- CARG-BC评分含8个预测因子,风险分组可区分3-5级化疗毒性风险。
- 开发队列低、中、高风险组毒性率分别为19%、54%、87%。
- 验证队列对应毒性率为27%、45%、76%,AUC为0.69。
核心结论
- CARG-BC评分可用于预测早期乳腺癌老年患者3-5级化疗毒性。
研究设计与样本
- 前瞻性评估16家机构≥65岁I-III期乳腺癌接受新辅助或辅助化疗的患者,共473例(开发队列283例,验证队列190例)。
- 采用逻辑回归最佳子集选择确定独立预测因子,并赋予加权评分。
主要发现
- 开发队列中46%患者发生3-5级化疗毒性。
- 开发队列低、中、高风险组(0-5、6-11、≥12分)毒性率分别为19%、54%、87%(P<.01)。
- 验证队列对应毒性率分别为27%、45%、76%。
- 开发队列AUC为0.75(95%CI 0.70-0.81),验证队列AUC为0.69(95%CI 0.62-0.77)。
- 风险分组与住院和剂量强度降低相关(P<.01)。
关键数值与推荐
- 预测因子及加权分:蒽环类使用(1分)、II或III期(3分)、计划治疗时长>3个月(4分)、肝功能异常(3分)、血红蛋白低(3分)、跌倒(4分)、行走受限(3分)、缺乏社会支持(3分)。
- 风险分组:低危0-5分,中危6-11分,高危≥12分。
临床怎么用
- 可用于≥65岁早期乳腺癌患者化疗前风险分层,辅助识别高危患者并个体化治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Limited tools exist to predict the risk of chemotherapy toxicity in older adults with early-stage breast cancer. METHODS: Patients of age ≥ 65 years with stage I-III breast cancer from 16 institutions treated with neoadjuvant or adjuvant chemotherapy were prospectively evaluated for geriatric and clinical features predictive of grade 3-5 chemotherapy toxicity. Logistic regression with best-subsets selection was used to identify and incorporate independent predictors of toxicity into a model with weighted variable scoring. Model performance was evaluated using area under the ROC curve (AUC) and goodness-of-fit statistics. The model was internally and externally validated. RESULTS: In 473 patients (283 in development and 190 in validation cohort), 46% developed grade 3-5 chemotherapy toxicities. Eight independent predictors were identified (each assigned weighted points): anthracycline use (1 point), stage II or III (3 points), planned treatment duration > 3 months (4 points), abnormal liver function (3 points), low hemoglobin (3 points), falls (4 points), limited walking (3 points), and lack of social support (3 points). We calculated risk scores for each patient and defined three risk groups: low (0-5 points), intermediate (6-11 points), or high (≥ 12 points). In the development cohort, the rates of grade 3-5 chemotherapy toxicity for these three groups were 19%, 54%, and 87%, respectively (P < .01). In the validation cohort, the corresponding toxicity rates were 27%, 45%, and 76%. The AUC was 0.75 (95% CI, 0.70 to 0.81) in the development cohort and 0.69 (95% CI, 0.62 to 0.77) in the validation cohort. Risk groups were also associated with hospitalizations and reduced dose intensity (P < .01). CONCLUSION: The Cancer and Aging Research Group-Breast Cancer (CARG-BC) score was developed and validated to predict grade 3-5 chemotherapy toxicity in older adults with early-stage breast cancer.
引用
- Magnuson A, Sedrak MS, Gross CP, et al. Development and Validation of a Risk Tool for Predicting Severe Toxicity in Older Adults Receiving Chemotherapy for Early-Stage Breast Cancer. J Clin Oncol. 2021. PMID: 33444080. doi:10.1200/JCO.20.02063
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。